Quotient Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Quotient stock.
View analyst ratings for Quotient or view top-rated stocks.

3 Wall Street analysts have issued 12-month price targets for Quotient's stock. Their QTNT stock forecasts range from $1.50 to $3.00. On average, they anticipate Quotient's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 798.6% from the stock's current price.
View analysts' price targets for Quotient or view top-rated stocks among Wall Street analysts.

Quotient's stock was trading at $2.59 at the beginning of 2022. Since then, QTNT shares have decreased by 90.3% and is now trading at $0.2504.
View the best growth stocks for 2022 here.

Quotient is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Quotient.

Quotient Limited (NASDAQ:QTNT) announced its earnings results on Friday, June, 24th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.09. During the same quarter in the prior year, the firm posted ($0.39) earnings per share.
View Quotient's earnings history.

Quotient updated its FY 2022 earnings guidance on Tuesday, June, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38.50 million-$38.50 million, compared to the consensus revenue estimate of $36.89 million.

Some companies that are related to Quotient include OncoCyte (OCX), MyMD Pharmaceuticals (MYMD), Aspira Women's Health (AWH), Lucira Health (LHDX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Biomerica (BMRA), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), ARCA biopharma (ABIO), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), StageZero Life Sciences (SZLSF), StageZero Life Sciences (GNWSF) and StageZero Life Sciences (GNWSD).
View all of QTNT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Highbridge Capital Management LLC (8.89%), BlackRock Inc. (5.25%), Clearbridge Investments LLC (4.15%), TimesSquare Capital Management LLC (2.65%), Vanguard Group Inc. (1.72%) and State Street Corp (1.46%). Company insiders that own Quotient stock include Edward Farrell, Jeremy Stackawitz, Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including Walleye Capital LLC, Walleye Capital LLC, BlackRock Inc., JPMorgan Chase & Co., TimesSquare Capital Management LLC, Vanguard Group Inc., and Northern Trust Corp.
View insider buying and selling activity for Quotient or view top insider-selling stocks.

QTNT stock was purchased by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, State Street Corp, GSA Capital Partners LLP, and Clearbridge Investments LLC. Company insiders that have bought Quotient stock in the last two years include Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient or or view top insider-buying stocks.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTNT stock can currently be purchased for approximately $0.25.

Quotient (NASDAQ:QTNT) has a market capitalization of $25.69 million and generates $38.51 million in revenue each year. The company earns $-125.13 million in net income (profit) each year or ($1.210010) on an earnings per share basis.

Quotient employs 426 workers across the globe.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The official website for Quotient is www.quotientbd.com. The company can be reached via phone at (122) 716-9800 or via email at [email protected].